Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Oral Antidiabetic Drugs Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Oral Antidiabetic Drugs Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Sulfonylureas
      • 1.3.3 Meglitinides
      • 1.3.4 Alpha-glucosidase inhibitors
    • 1.4 Market Segment by Application
      • 1.4.1 Global Oral Antidiabetic Drugs Market Share by Application (2019-2025)
      • 1.4.2 Hospitals
      • 1.4.3 Clinics
      • 1.4.4 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Oral Antidiabetic Drugs Market Size
      • 2.1.1 Global Oral Antidiabetic Drugs Revenue 2014-2025
      • 2.1.2 Global Oral Antidiabetic Drugs Sales 2014-2025
    • 2.2 Oral Antidiabetic Drugs Growth Rate by Regions
      • 2.2.1 Global Oral Antidiabetic Drugs Sales by Regions 2014-2019
      • 2.2.2 Global Oral Antidiabetic Drugs Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Oral Antidiabetic Drugs Sales by Manufacturers
      • 3.1.1 Oral Antidiabetic Drugs Sales by Manufacturers 2014-2019
      • 3.1.2 Oral Antidiabetic Drugs Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Oral Antidiabetic Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Oral Antidiabetic Drugs Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Oral Antidiabetic Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.3 Oral Antidiabetic Drugs Price by Manufacturers
    • 3.4 Key Manufacturers Oral Antidiabetic Drugs Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Oral Antidiabetic Drugs Market
    • 3.6 Key Manufacturers Oral Antidiabetic Drugs Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Sulfonylureas Sales and Revenue (2014-2019)
      • 4.1.2 Meglitinides Sales and Revenue (2014-2019)
      • 4.1.3 Alpha-glucosidase inhibitors Sales and Revenue (2014-2019)
    • 4.2 Global Oral Antidiabetic Drugs Sales Market Share by Type
    • 4.3 Global Oral Antidiabetic Drugs Revenue Market Share by Type
    • 4.4 Oral Antidiabetic Drugs Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Oral Antidiabetic Drugs Sales by Application

    6 United States

    • 6.1 United States Oral Antidiabetic Drugs Breakdown Data by Company
    • 6.2 United States Oral Antidiabetic Drugs Breakdown Data by Type
    • 6.3 United States Oral Antidiabetic Drugs Breakdown Data by Application

    7 European Union

    • 7.1 European Union Oral Antidiabetic Drugs Breakdown Data by Company
    • 7.2 European Union Oral Antidiabetic Drugs Breakdown Data by Type
    • 7.3 European Union Oral Antidiabetic Drugs Breakdown Data by Application

    8 China

    • 8.1 China Oral Antidiabetic Drugs Breakdown Data by Company
    • 8.2 China Oral Antidiabetic Drugs Breakdown Data by Type
    • 8.3 China Oral Antidiabetic Drugs Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Oral Antidiabetic Drugs Breakdown Data by Company
    • 9.2 Rest of World Oral Antidiabetic Drugs Breakdown Data by Type
    • 9.3 Rest of World Oral Antidiabetic Drugs Breakdown Data by Application
    • 9.4 Rest of World Oral Antidiabetic Drugs Breakdown Data by Countries
      • 9.4.1 Rest of World Oral Antidiabetic Drugs Sales by Countries
      • 9.4.2 Rest of World Oral Antidiabetic Drugs Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Eli Lilly
      • 10.1.1 Eli Lilly Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Oral Antidiabetic Drugs
      • 10.1.4 Oral Antidiabetic Drugs Product Introduction
      • 10.1.5 Eli Lilly Recent Development
    • 10.2 Abbott
      • 10.2.1 Abbott Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Oral Antidiabetic Drugs
      • 10.2.4 Oral Antidiabetic Drugs Product Introduction
      • 10.2.5 Abbott Recent Development
    • 10.3 Biocon
      • 10.3.1 Biocon Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Oral Antidiabetic Drugs
      • 10.3.4 Oral Antidiabetic Drugs Product Introduction
      • 10.3.5 Biocon Recent Development
    • 10.4 Sanofi
      • 10.4.1 Sanofi Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Oral Antidiabetic Drugs
      • 10.4.4 Oral Antidiabetic Drugs Product Introduction
      • 10.4.5 Sanofi Recent Development
    • 10.5 Sunpharma
      • 10.5.1 Sunpharma Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Oral Antidiabetic Drugs
      • 10.5.4 Oral Antidiabetic Drugs Product Introduction
      • 10.5.5 Sunpharma Recent Development
    • 10.6 Novartis
      • 10.6.1 Novartis Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Oral Antidiabetic Drugs
      • 10.6.4 Oral Antidiabetic Drugs Product Introduction
      • 10.6.5 Novartis Recent Development
    • 10.7 Novo Nordisk
      • 10.7.1 Novo Nordisk Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Oral Antidiabetic Drugs
      • 10.7.4 Oral Antidiabetic Drugs Product Introduction
      • 10.7.5 Novo Nordisk Recent Development
    • 10.8 Merck
      • 10.8.1 Merck Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Oral Antidiabetic Drugs
      • 10.8.4 Oral Antidiabetic Drugs Product Introduction
      • 10.8.5 Merck Recent Development
    • 10.9 Pfizer
      • 10.9.1 Pfizer Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Oral Antidiabetic Drugs
      • 10.9.4 Oral Antidiabetic Drugs Product Introduction
      • 10.9.5 Pfizer Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Oral Antidiabetic Drugs Sales Channels
      • 11.2.2 Oral Antidiabetic Drugs Distributors
    • 11.3 Oral Antidiabetic Drugs Customers

    12 Market Forecast

    • 12.1 Global Oral Antidiabetic Drugs Sales and Revenue Forecast 2019-2025
    • 12.2 Global Oral Antidiabetic Drugs Sales Forecast by Type
    • 12.3 Global Oral Antidiabetic Drugs Sales Forecast by Application
    • 12.4 Oral Antidiabetic Drugs Forecast by Regions
      • 12.4.1 Global Oral Antidiabetic Drugs Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Oral Antidiabetic Drugs Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Diabetes mellitus is a group of a metabolic disorder caused when the body is unable to produce required quantity of Insulin. Insulin is a hormone secreted by beta cells of the islet of Langerhans of the pancreas. Various symptoms associated with diabetes disorder include recurrent urination, increased thirst, and hunger. Diabetes can cause much chronic complication if left untreated. Some of them include acute complications like diabetic ketoacidosis, chronic kidney failure, foot ulcers, and damage to the eyes.
      In 2019, the market size of Oral Antidiabetic Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Oral Antidiabetic Drugs.

      This report studies the global market size of Oral Antidiabetic Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Oral Antidiabetic Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Eli Lilly
      Abbott
      Biocon
      Sanofi
      Sunpharma
      Novartis
      Novo Nordisk
      Merck
      Pfizer

      Market Segment by Product Type
      Sulfonylureas
      Meglitinides
      Alpha-glucosidase inhibitors

      Market Segment by Application
      Hospitals
      Clinics
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Oral Antidiabetic Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Oral Antidiabetic Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Oral Antidiabetic Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now